SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $10.00.

SABS has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Chardan Capital restated a “buy” rating and set a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, December 18th. UBS Group initiated coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Guggenheim assumed coverage on SAB Biotherapeutics in a report on Friday, December 19th. They set a “buy” rating and a $15.00 price target for the company.

Hedge Funds Weigh In On SAB Biotherapeutics

Several large investors have recently bought and sold shares of SABS. HB Wealth Management LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter worth $618,000. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics during the 3rd quarter worth about $30,000. Vivo Capital LLC bought a new position in shares of SAB Biotherapeutics during the 3rd quarter worth about $22,954,000. RA Capital Management L.P. acquired a new position in shares of SAB Biotherapeutics during the third quarter valued at about $8,847,000. Finally, Woodline Partners LP bought a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $5,730,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Trading Down 0.7%

NASDAQ:SABS opened at $4.00 on Friday. The company’s 50 day moving average is $3.84 and its 200-day moving average is $2.93. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $6.60. The firm has a market cap of $190.44 million, a price-to-earnings ratio of -1.29 and a beta of 0.58.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.38. Equities analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.